| scholarly article | Q13442814 |
| P356 | DOI | 10.3816/CLC.2007.N.041 |
| P698 | PubMed publication ID | 18186959 |
| P50 | author | David R Gandara | Q73567194 |
| P2093 | author name string | Paul H Gumerlock | |
| Philip C Mack | |||
| Primo N Lara | |||
| Angela M Davies | |||
| Brandi Pryde | |||
| Christopher M Mahaffey | |||
| William Holland | |||
| P2860 | cites work | Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lin | Q40141617 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| erlotinib | Q418369 | ||
| docetaxel | Q420436 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 548-553 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Clinical Lung Cancer | Q332299 |
| P1476 | title | Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation | |
| P478 | volume | 8 |
| Q34336217 | A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors |
| Q33911180 | A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer |
| Q43563722 | A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study |
| Q36740744 | A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments |
| Q35621694 | Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma |
| Q39102975 | Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines |
| Q36217036 | Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers |
| Q38381681 | Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab |
| Q41892153 | Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. |
| Q53257189 | Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts. |
| Q38524526 | Experience with erlotinib in the treatment of non-small cell lung cancer |
| Q34503883 | Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations |
| Q35560779 | Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial |
| Q38549723 | Is epidermal growth factor receptor tyrosine kinase inhibitor in combination with cytotoxic chemotherapy a better treatment option for patients with EGFR-mutated non-small-cell lung cancer? |
| Q34560236 | Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib |
| Q43780769 | Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. |
| Q39336275 | Novel hydrophilic docetaxel (CQMU-0519) analogue inhibits proliferation and induces apoptosis in human A549 lung, SKVO3 ovarian and MCF7 breast carcinoma cell lines |
| Q26859993 | Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor |
| Q35667782 | Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC) |
| Q38682189 | Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms |
| Q35054633 | Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results |
| Q36816522 | Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors |
| Q35951086 | Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer |
| Q41452420 | Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. |
| Q37104233 | Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. |
| Q36230591 | Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells |
| Q53058056 | Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms. |
| Q41678123 | Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors |
| Q39984247 | Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer |
| Q37624426 | Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy |
| Q47646868 | Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro |
| Q37009125 | Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer |
| Q41969486 | Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines |
| Q39499521 | Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation |
| Q37765472 | Targeted therapy in non-small-cell lung cancer--is it becoming a reality? |
| Q37781113 | Targeted therapy: an evolving world of lung cancer. |
| Q41926158 | The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib |
| Q28396304 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer |
Search more.